Fig. 1From: Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trialSchematic representation of the study design. MMF, mycophenolate mofetil; MP, methylprednisolone; pred, oral prednisolone; B, belimumab; R, rituximab; EoS, end of study; w, weekBack to article page